Pegarginase (Bio-Cancer Treatment International)

N/A

Report date: 2022/08/29 20:00:24

Base Information

Drug NamePegarginase (Bio-Cancer Treatment International)
Drug Alias NameRecombinant human arginase 1PEG-arginasePEGylated recombinant human arginaseBCT-100PEG-BCT-100
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionArginase replacements
TargetsArginine
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsCarcinoma, Hepatocellular +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsAustralia +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBio-Cancer Treatment International Ltd
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Birmingham
Inactive CompaniesBio-Cancer Treatment International Ltd
Active IndicationsSolid tumoursLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsProstatic NeoplasmsCarcinoma, HepatocellularMelanoma +[6] 

Other Information

ATC CodeN/A
Related LinksN/A